Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy.

Chari A, Vogl DT, Jagannath S, Jasielec J, Unger TJ, DeCastro A, Shah J, Kauffman M, Shacham S, Jakubowiak A. Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. Br J Haematol. 2020 05; 189(4):e126-e130.

View in: PubMed

collapse authors with profiles